BioNTech SE (BNTX)

BioNTech SE Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	930.3	9,434	10,293	15.2	-179.1
Depreciation & Amortization	183.4	123.3	75.2	38.7	33.9
Share-Based Compensation	-714.8	56.8	80.5	32.1	30.2
Other Operating Activities	4,973	3,963	-9,558.5	-99.5	-83.5
Operating Cash Flow	5,371	13,577	889.7	-13.5	-198.5
Operating Cash Flow Growth	-60.44%	1426.06%	-	-	-
Capital Expenditures	-705.5	-362.7	-150.6	-84.2	-71.1
Acquisitions	-336.9	0	-20.8	-60.6	-6.1
Change in Investments	-5,912.1	327.4	-394.7	0	0
Investing Cash Flow	-6,954.5	-35.3	-566.1	-144.8	-77.2
Dividends Paid	0	-484.3	0	0	0
Share Issuance / Repurchase	-738.5	-875.9	160.9	753	375.4
Debt Issued / Paid	-40.1	-59.1	-66.7	156	7.9
Other Financing Activities	-	-	-	-14.3	-
Financing Cash Flow	-778.6	-1,419.3	94.2	894.7	383.3
Exchange Rate Effect	-14.5	60.1	64.7	-45.3	0
Net Cash Flow	-2,361.7	12,123	417.8	736.4	107.6
Free Cash Flow	4,666	13,215	739.1	-97.7	-269.6
Free Cash Flow Growth	-64.69%	1687.94%	-	-	-
Free Cash Flow Margin	122.18%	76.34%	3.89%	-20.26%	-248.25%
Free Cash Flow Per Share	19.63	54.38	3.02	-0.43	-1.19

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).